Montelukast Arrow Lab

Montelukast, the active ingredient in Montelukast Arrow Lab, is a leukotriene receptor antagonist presented as a tablet for oral use. It helps manage asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Arrow Lab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions. - Asthma: reduces frequency and severity of asthma attacks and improves symptom control. - Exercise‑induced bronchoconstriction: prevents narrowing of airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic triggers.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: symptoms of cold or flu. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Diarrhoea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: depression or suicidal thoughts. - Allergic reactions: hives, swelling, or anaphylaxis. - Liver enzyme elevation: abnormal liver function tests. - Stevens‑Johnson syndrome: severe skin blistering. - Angioedema: rapid swelling of face or throat.

Before using Montelukast, consider the following safety measures. - Pregnancy: consult a healthcare professional; safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Liver disease: use with caution; monitor hepatic function. - Concomitant asthma therapy: do not replace inhaled steroids without medical advice. - Age restrictions: follow prescribing information for pediatric use. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines; monitoring is advised.

Major Interactions (Avoid): - Phenobarbital: may lower montelukast plasma concentrations. - Rifampin: can reduce therapeutic effect by inducing metabolism. - Ketoconazole: may increase montelukast levels, raising risk of side effects.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation. - Theophylline: may enhance bronchodilator effect. - Beta‑agonists: additive bronchodilation; observe for excessive response.